Dyne Therapeutics, Inc. (DYN)
Every FINRA and SEC series the site collects for Dyne Therapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
20.8M
Short interest
settlement 2026-08-31
13.5
Days to cover
-3.1% vs prior
51.7%
Short share of volume
2026-09-11
55,528
Fails to deliver
settlement 2026-07-31
-$96.0M
Insider flow, 90 days
0 buys, 41 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 31 August 2026, short interest in DYN is 20,790,669 shares, down 1,179,871 shares over the last month. Over the last 48 readings it ranged from 7,660,014 shares (13 September 2024) to 25,528,873 shares (30 May 2025). At the reported average volume of 1.5M shares a day that is 13.5 days to cover, a crowded short.
Embed this chartkeeps the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/dyn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 20,790,669 | -3.1% | 1,535,761 | 13.54 |
| 2026-08-14 | 21,459,799 | -2.3% | 1,960,545 | 10.95 |
| 2026-07-31 | 21,970,540 | +2.2% | 3,060,368 | 7.18 |
| 2026-07-15 | 21,491,180 | -3.6% | 2,019,028 | 10.64 |
| 2026-06-30 | 22,302,023 | -2.2% | 2,790,378 | 7.99 |
| 2026-06-15 | 22,812,489 | +2.4% | 1,591,982 | 14.33 |
| 2026-05-29 | 22,275,672 | +6.2% | 1,523,070 | 14.63 |
| 2026-05-15 | 20,983,648 | +1.2% | 1,251,838 | 16.76 |
| 2026-04-30 | 20,733,946 | -4.5% | 1,811,499 | 11.45 |
| 2026-04-15 | 21,704,095 | +6.0% | 1,615,478 | 13.44 |
| 2026-03-31 | 20,465,591 | +7.1% | 2,422,961 | 8.45 |
| 2026-03-13 | 19,103,364 | -1.1% | 2,899,945 | 6.59 |
| 2026-02-27 | 19,317,547 | +0.9% | 1,769,968 | 10.91 |
| 2026-02-13 | 19,152,510 | -0.2% | 1,662,304 | 11.52 |
| 2026-01-30 | 19,189,031 | +1.6% | 2,103,302 | 9.12 |
| 2026-01-15 | 18,889,124 | +9.2% | 2,269,509 | 8.32 |
| 2025-12-31 | 17,295,386 | +15.7% | 1,917,931 | 9.02 |
| 2025-12-15 | 14,949,400 | -14.4% | 4,208,510 | 3.55 |
| 2025-11-28 | 17,458,619 | +2.0% | 2,452,241 | 7.12 |
| 2025-11-14 | 17,111,938 | +13.2% | 2,624,140 | 6.52 |
| 2025-10-31 | 15,118,377 | -11.6% | 3,187,488 | 4.74 |
| 2025-10-15 | 17,097,410 | -3.8% | 2,311,080 | 7.40 |
| 2025-09-30 | 17,774,449 | +16.1% | 2,808,136 | 6.33 |
| 2025-09-15 | 15,303,535 | -4.6% | 2,003,038 | 7.64 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of DYN volume is 51.7%, down 8.2 points over the last five sessions. Over the last 52 readings it ranged from 25.6% (19 August 2026) to 85.4% (6 July 2026). The latest reading is 2.8 points above the 30-session average of 48.9%, on 1.7M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 890K | 1.7M | 51.7% | 11,477 |
| 2026-09-10 | 1.2M | 2.1M | 56.7% | 58 |
| 2026-09-09 | 1.5M | 2.6M | 59.2% | 26,021 |
| 2026-09-08 | 3.7M | 8.5M | 43.1% | 185,745 |
| 2026-09-04 | 254K | 650K | 39.0% | 308 |
| 2026-09-03 | 281K | 469K | 59.9% | 0 |
| 2026-09-02 | 251K | 670K | 37.4% | 1,590 |
| 2026-09-01 | 390K | 844K | 46.2% | 1,000 |
| 2026-08-31 | 252K | 467K | 54.1% | 291 |
| 2026-08-28 | 199K | 325K | 61.4% | 0 |
| 2026-08-27 | 163K | 318K | 51.3% | 0 |
| 2026-08-26 | 233K | 490K | 47.6% | 2,933 |
| 2026-08-25 | 207K | 605K | 34.2% | 0 |
| 2026-08-24 | 408K | 631K | 64.7% | 12,927 |
| 2026-08-21 | 253K | 431K | 58.8% | 0 |
| 2026-08-20 | 384K | 516K | 74.4% | 628 |
| 2026-08-19 | 233K | 911K | 25.6% | 1,203 |
| 2026-08-18 | 240K | 489K | 49.0% | 152 |
| 2026-08-17 | 160K | 503K | 31.9% | 0 |
| 2026-08-14 | 433K | 754K | 57.4% | 6,136 |
| 2026-08-13 | 536K | 917K | 58.4% | 254,833 |
| 2026-08-12 | 222K | 834K | 26.7% | 2,958 |
| 2026-08-11 | 226K | 534K | 42.3% | 0 |
| 2026-08-10 | 477K | 822K | 58.0% | 4,163 |
| 2026-08-07 | 337K | 935K | 36.0% | 3,428 |
| 2026-08-06 | 209K | 327K | 63.8% | 3,408 |
| 2026-08-05 | 263K | 476K | 55.1% | 6,643 |
| 2026-08-04 | 375K | 994K | 37.7% | 4,625 |
| 2026-08-03 | 320K | 959K | 33.3% | 3,024 |
| 2026-07-31 | 334K | 646K | 51.7% | 58 |
Fails to deliver
SEC, by settlement date. JSONAs of 31 July 2026, the fails-to-deliver balance in DYN is 55,528 shares, up 55,216 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (11 May 2026) to 285,203 shares (11 March 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-07-31 | 55,528 | $25.73 | $1.4M |
| 2026-07-28 | 312 | $25.63 | $8K |
| 2026-07-23 | 19 | $23.21 | $441 |
| 2026-07-22 | 43 | $23.83 | $1K |
| 2026-07-21 | 559 | $23.45 | $13K |
| 2026-07-17 | 581 | $22.72 | $13K |
| 2026-07-14 | 3,399 | $23.64 | $80K |
| 2026-07-13 | 2,202 | $23.42 | $52K |
| 2026-07-01 | 75,144 | $22.21 | $1.7M |
| 2026-06-30 | 162 | $21.26 | $3K |
| 2026-06-22 | 263,431 | $19.80 | $5.2M |
| 2026-06-12 | 2,829 | $17.95 | $51K |
| 2026-06-10 | 71 | $17.92 | $1K |
| 2026-06-08 | 36,267 | $17.04 | $618K |
| 2026-06-03 | 1,353 | $17.24 | $23K |
| 2026-06-01 | 96 | $19.33 | $2K |
| 2026-05-26 | 2 | $17.37 | $35 |
| 2026-05-20 | 8,179 | $15.92 | $130K |
| 2026-05-12 | 3,497 | $18.46 | $65K |
| 2026-05-11 | 1 | $17.61 | $18 |
| 2026-05-07 | 5 | $18.84 | $94 |
| 2026-04-22 | 2,264 | $19.21 | $43K |
| 2026-04-20 | 41,278 | $20.41 | $842K |
| 2026-04-02 | 3,836 | $18.10 | $69K |
| 2026-03-27 | 14,086 | $18.55 | $261K |
| 2026-03-25 | 51,519 | $17.85 | $920K |
| 2026-03-12 | 848 | $19.99 | $17K |
| 2026-03-11 | 285,203 | $19.78 | $5.6M |
| 2026-03-06 | 53,575 | $15.20 | $814K |
| 2026-03-04 | 255 | $14.60 | $4K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at DYN reported 41 open-market sells worth $96.0M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Friedl-Naderer Johanna (Chief Commercial Officer) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 185 | $18.88 | $3K | 153K |
| 2026-09-08 | Kerr Douglas | Chief Medical Officer | Sell | 1K | $18.88 | $24K | 163K |
| 2026-09-08 | Cox John | CEO & President | Sell | 6K | $18.88 | $107K | 358K |
| 2026-09-04 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 900 | $24.35 | $22K | 153K |
| 2026-09-04 | Kerr Douglas | Chief Medical Officer | Sell | 4K | $24.35 | $91K | 164K |
| 2026-08-14 | Rhodes Jason P | n/a | Sell | 322K | $25.00 | $8.1M | 429K |
| 2026-08-14 | Rhodes Jason P | n/a | Sell | 478K | $25.00 | $12.0M | 567K |
| 2026-08-14 | Rhodes Jason P | n/a | Sell | 1.4M | $25.00 | $34.0M | 2.4M |
| 2026-08-13 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 226 | $26.28 | $6K | 154K |
| 2026-08-13 | Kerr Douglas | Chief Medical Officer | Sell | 2K | $26.28 | $41K | 168K |
| 2026-08-13 | Lucera Erick | Chief Financial Officer | Sell | 2K | $26.28 | $47K | 120K |
| 2026-08-13 | Rhodes Jason P | n/a | Sell | 64K | $26.20 | $1.7M | 751K |
| 2026-08-13 | Rhodes Jason P | n/a | Sell | 94K | $26.20 | $2.5M | 1.0M |
| 2026-08-13 | Rhodes Jason P | n/a | Sell | 268K | $26.20 | $7.0M | 3.8M |
| 2026-08-13 | Cox John | CEO & President | Sell | 5K | $26.28 | $131K | 363K |
| 2026-07-27 | Kersten Dirk | n/a | Sell | 5K | $26.04 | $140K | 3.6M |
| 2026-07-27 | Kersten Dirk | n/a | Sell | 256K | $25.50 | $6.5M | 3.6M |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 52K | $21.14 | $1.1M | 1.3M |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 41K | $21.14 | $860K | 976K |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 103K | $21.14 | $2.2M | 4.5M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 64K | $21.28 | $1.4M | 1.0M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 82K | $21.28 | $1.7M | 1.4M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 163K | $21.28 | $3.5M | 4.6M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 5K | $21.10 | $106K | 1.1M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 13K | $21.10 | $268K | 4.7M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 6K | $21.10 | $135K | 1.5M |
| 2026-06-25 | Lucera Erick | Chief Financial Officer | Sell | 2K | $20.37 | $48K | 122K |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 51K | $21.02 | $1.1M | 4.8M |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 25K | $21.02 | $534K | 1.5M |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 20K | $21.02 | $420K | 1.1M |
| 2026-06-23 | Kersten Dirk | Director | Sell | 72K | $21.04 | $1.5M | 3.8M |
| 2026-06-23 | Kersten Dirk | Director | Sell | 2K | $21.47 | $36K | 3.8M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 39K | $21.13 | $827K | 1.5M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 78K | $21.13 | $1.6M | 4.8M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 31K | $21.13 | $650K | 1.1M |
| 2026-06-22 | Kersten Dirk | Director | Sell | 191K | $20.57 | $3.9M | 3.9M |
| 2026-06-18 | Kersten Dirk | Director | Sell | 47K | $20.07 | $941K | 4.1M |
| 2026-06-17 | Kersten Dirk | Director | Sell | 37K | $20.14 | $754K | 4.2M |
| 2026-06-16 | Cox John | CEO & President | Sell | 3K | $18.33 | $49K | 368K |
| 2026-06-16 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 145 | $18.33 | $3K | 154K |
| 2026-06-16 | Kerr Douglas | Chief Medical Officer | Sell | 887 | $18.33 | $16K | 169K |
| 2026-06-08 | Posner Brian S | n/a | Buy | 2K | $16.94 | $34K | 25K |
| 2026-06-03 | Posner Brian S | n/a | Buy | 3K | $17.48 | $44K | 23K |
| 2026-05-26 | Posner Brian S | n/a | Buy | 2K | $18.21 | $36K | 20K |
| 2026-05-20 | Posner Brian S | n/a | Buy | 3K | $17.12 | $43K | 18K |
| 2026-05-13 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 228 | $18.36 | $4K | 154K |
| 2026-05-13 | Kerr Douglas | Chief Medical Officer | Sell | 2K | $18.36 | $29K | 170K |
| 2026-05-13 | Lucera Erick | Chief Financial Officer | Sell | 1K | $18.36 | $27K | 124K |
| 2026-05-13 | Cox John | CEO & President | Sell | 3K | $18.36 | $61K | 371K |
| 2026-05-06 | Rhodes Jason P | n/a | Sell | 17K | $18.18 | $313K | 1.1M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for DYN worth $7.1M at the prices reported; 7 in the last 90 days worth $7.1M. Latest: Kerr Douglas filed on 2026-09-08 to sell 35 shares ($661) from 2026-09-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-08 | Kerr DouglasOfficer | 35 | $661 | 0.000% | 2026-09-08 | Stifel Nicolaus & Company Inc |
| 2026-09-08 | Cox JohnOfficer | 6K | $107K | 0.003% | 2026-09-08 | Stifel Nicolaus & Company Inc |
| 2026-09-04 | Kerr DouglasOfficer | 5K | $122K | 0.003% | 2026-09-04 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Lucera ErickOfficer | 2K | $47K | 0.001% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Kerr DouglasOfficer | 2K | $64K | 0.001% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Cox JohnOfficer | 5K | $131K | 0.003% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-07-27 | ForDyne B.V.Affiliate | 261K | $6.7M | 0.158% | 2026-07-27 | UBS Financial Services Inc. |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON21 holders above 5% have filed on DYN, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 16.2% of the class (26,578,437 shares), filed 2026-03-06 for an event on 2026-02-28.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 7 | JANUS HENDERSON GROUP Ltd.parent holding company | 12.0M | 7.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Fund XI, L.P.partnership | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates XI, L.P.partnership | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates XI, LLCother entity | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity II, L.P.partnership | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Opportunity Fund II, L.P.partnership | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity II, LLCother entity | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Opportunity Fund I, L.P.partnership | 976K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity I, L.P.partnership | 976K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity I, LLCother entity | 976K | 0.5% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 11.2M | 6.8% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 11.2M | 6.8% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 11.5M | 7.0% | 2026-06-30 |
| 2026-05-06 | 13G | Abigail P. Johnsonindividual | 8.9M | 5.4% | 2026-03-31 |
| 2026-05-06 | 13G | FMR LLCparent holding company | 8.9M | 5.4% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-06 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 26.6M | 16.2% | 2026-02-28 |
| 2026-02-17 | 13G/Ano. 5 | JANUS HENDERSON GROUP PLCparent holding company | 13.9M | 8.5% | 2025-12-31 |
| 2026-01-08 | 13G | T. Rowe Price Investment Management, Inc.investment adviser | 17.5M | 10.7% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 4 | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 14.7M | 10.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | Peter Kolchinskyparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | RA Capital Healthcare Fund, L.P.partnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | RA Capital Management, L.P.investment adviser, partnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | Rajeev Shahparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates XI, L.P.partnership | 5.7M | 4.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Fund XI, L.P.partnership | 5.7M | 4.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates XI, LLCother entity | 5.7M | 4.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Opportunity Fund II, L.P.partnership | 2.0M | 1.4% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates Opportunity II, LLCother entity | 2.0M | 1.4% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates Opportunity II, LPpartnership | 2.0M | 1.4% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates Opportunity I, LLCother entity | 1.5M | 1.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Associates Opportunity I, L.P.partnership | 1.5M | 1.0% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 5 | Atlas Venture Opportunity Fund I, L.P.partnership | 1.5M | 1.0% | 2025-09-30 |
13F holders
Tracked managers holding DYN at their latest 13F. JSON7 of the 30 tracked managers held DYN at their latest 13F, $54.1M in total at quarter-end prices. Citadel Advisors is the largest at $26.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 1.2M | $26.4M | 0.00% | +947K |
| Millennium Management | 2026-06-30 | 432K | $9.6M | 0.00% | new or n/a |
| Renaissance Technologies | 2026-06-30 | 361K | $8.0M | 0.01% | -173K |
| Fisher Asset Management | 2026-06-30 | 299K | $6.6M | 0.00% | -25K |
| AQR Capital Management | 2026-06-30 | 84K | $1.9M | 0.00% | -184 |
| D. E. Shaw & Co. | 2026-06-30 | 60K | $1.3M | 0.00% | +19K |
| Two Sigma Investments | 2026-06-30 | 14K | $315K | 0.00% | -145K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$403.2M of operating cash flow. As of 2026-06-30, cash was $676.1M against $199.3M of debt.
- Cash
- $676.1M
- Debt
- $199.3M
- Equity
- $702.2M
- Total assets
- $994.0M
- Shares outstanding
- 186,746,431
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | n/a | -$178.6M | n/a | -1.08 |
| Q1 2026 | 2026-03-31 | n/a | -$120.9M | n/a | -0.73 |
| Q3 2025 | 2025-09-30 | n/a | -$108.0M | n/a | -0.76 |
| Q2 2025 | 2025-06-30 | n/a | -$110.9M | n/a | -0.97 |
| Q1 2025 | 2025-03-31 | n/a | -$115.4M | n/a | -1.05 |
| Q3 2024 | 2024-09-30 | n/a | -$97.1M | n/a | -0.96 |
| Q2 2024 | 2024-06-30 | n/a | -$65.1M | n/a | -0.70 |
| Q1 2024 | 2024-03-31 | n/a | -$65.6M | n/a | -0.81 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | n/a | -$403.2M | $1.9M | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | n/a | -$292.4M | $2.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | n/a | -$188.2M | $729K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | n/a | -$153.6M | $3.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$149.3M | -$119.6M | $3.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
Dyne Therapeutics, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Dyne Therapeutics, Inc. (DYN), SEC CIK 1818794, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-07-31.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1818794Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 14 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- REGNREGENERON PHARMACEUTICALS, INC.
- LLYELI LILLY & Co
- VRTXVERTEX PHARMACEUTICALS INC / MA
- ALNYALNYLAM PHARMACEUTICALS, INC.
- BMYBRISTOL MYERS SQUIBB CO
- CYTKCYTOKINETICS INC
- PTCTPTC THERAPEUTICS, INC.
- INSMINSMED Inc
- IONSIONIS PHARMACEUTICALS INC
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- JNJJOHNSON & JOHNSON
- CORTCORCEPT THERAPEUTICS INC
- ABBVAbbVie Inc.
- ROIVRoivant Sciences Ltd.
- ABTABBOTT LABORATORIES
- BBIOBridgeBio Pharma, Inc.
- KNSAKiniksa Pharmaceuticals International, plc
- JAZZJazz Pharmaceuticals plc
- ARQTArcutis Biotherapeutics, Inc.
- VTRSViatris Inc
- PRGOPERRIGO Co plc
- ARDXARDELYX, INC.
Datasets
Frequently Asked Questions
How much of DYN is sold short?
What is DYN's daily short volume?
Does DYN have fails to deliver?
Are DYN insiders buying or selling?
Have DYN insiders filed to sell?
Who owns more than 5% of DYN?
What did DYN report last quarter?
Which funds hold DYN?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.